PMA device
Elecsys total PSA, total PSA CalSet II
Roche Diagnostics Corp. · Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF, Class III) · First FDA decision Nov 22, 2000, newest Mar 23, 2023Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
11
PMA pathway
Device trials
2
Naming "Elecsys"
MAUDE reports
7,859
Brand "Elecsys", since 2015
PubMed studies
1,828
Mentioning "Elecsys"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Elecsys total PSA, total PSA CalSet II
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 11 decisions filed under this name.
- Elecsys total PSA, total PSA CalSet IIPMA supplement
P990056-S039 · Decided Mar 23, 2023 · 177 days after receipt · Normal 180 Day Track
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
- Elecsys total PSAPMA supplement
P990056-S037 · Decided May 12, 2020 · 180 days after receipt · Normal 180 Day Track
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
- Elecsys total PSAPMA supplement
P990056-S035 · Decided Apr 24, 2019 · 180 days after receipt · Normal 180 Day Track No User Fee
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P990056-S013, P990056-S008, P990056-S007, P990056-S003, P990056
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Elecsys", any status and sponsor, newest update first.
Dragonfly Research, LLCAcademic, hospital or other
NCT04837651 · 48 participants · Start Mar 2, 2021 · Primary completion Jul 1, 2021
Device: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test; T-Detect COVID T-cell blood test · For: Multiple Sclerosis; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System and 5 more
Sites: Wellesley, Massachusetts
Hoffmann-La RocheNot on our public-company list
NCT00519961 · 1,800 participants (planned) · Start Feb 2007 · Primary completion Sep 2010
Device: Elecsys®proBNP · For: Peripheral Vascular Disease
Sites: Dublin, Ireland; Rotterdam, Netherlands
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Elecsys", and for the whole product code for context.
This brand
7,859 reports: 7,766 malfunction, 61 injury, 0 death
Whole product code MTF
390 reports: 373 malfunction, 17 injury, 0 death
Newest reports for this brand
- Elecsys Folate IIIMalfunction
1823260-2026-04537 · Received Oct 30, 2026 · Event dated Oct 6, 2026
Device type: Acid, Folic, Radioimmunoassay (CGN)
Device problem as coded: Incorrect Measurement
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Elecsys Estradiol IIIInjury
1823260-2026-04489 · Received Oct 29, 2026 · Event dated Dec 29, 2025
Device type: Radioimmunoassay, Estradiol (CHP)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings; Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Elecsys HBsAg IIMalfunction
1823260-2026-04492 · Received Oct 29, 2026 · Event dated Oct 6, 2026
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM)
Device problem as coded: False Positive Result; Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Elecsys"[tiab]. The summary above synthesizes these.
- Drugs for dementia.
Med Lett Drugs Ther · 2026
- Humoral Immune Response to SARS-CoV-2.
Herroelen PH, Martens GA, De Smet D, et al. · Am J Clin Pathol · 2020Research Support, Non-U.S. Gov't
- Elecsys Cerebrospinal Fluid Immunoassays Accurately Detect Alzheimer's Disease Regardless of Concomitant Small Vessel Disease.
Ortner M, Lanz K, Goldhardt O, et al. · J Alzheimers Dis · 2023Research Support, Non-U.S. Gov't
- Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts.
Hibar DP, Bauer A, Rabe C, et al. · Alzheimers Dement · 2026
- Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSF.
Manuilova E, Schrurs I, Rutz S, et al. · Alzheimers Dement · 2025
- Clinical Application Evaluation of Elecsys® HIV Duo Assay in Southwest China.
Yang M, Yang W, Shi W, et al. · Front Cell Infect Microbiol · 2022
- Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections.
Grunau B, Tom J, Asamoah-Boaheng M, et al. · Open Forum Infect Dis · 2022
- Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay.
Salvagno GL, Pighi L, De Nitto S, et al. · Pract Lab Med · 2022
- Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies.
Aijaz J, Kanani F, Naseer F · J Clin Virol Plus · 2023
- Multicenter performance evaluation of the Elecsys HCV Duo immunoassay.
Majchrzak M, Bronner K, Laperche S, et al. · J Clin Virol · 2022Multicenter Study, Research Support, Non-U.S. Gov't
- Elecsys® AMH assay: Determination of Anti-Müllerian hormone levels and evaluation of the relationship between superovulation response in Holstein dairy cows.
Koca D, Aktar A, Turgut AO, et al. · Vet Med Sci · 2024Research Support, Non-U.S. Gov't
- Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease.
Blennow K, Stomrud E, Zetterberg H, et al. · Clin Chem Lab Med · 2023
Other devices of this type
Also filed under product code MTF.
- ARCHITECT Total PSA, Alinity i Total PSAAbbott Laboratories · PMA 2023
- Access Hybritech PSABeckman Coulter, Inc. · PMA 2024
- Dimension Vista Tpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Atellica IM Total PSA II (tPSAII)Siemens Healthcare Diagnostics, Inc. · PMA 2026
- Advia Centaur Psa AssaySiemens Healthcare Diagnostics · PMA 2017
- Axsym Total PsaAbbott Laboratories · PMA 2011
- Abbott Architect Total PsaAbbott Laboratories · PMA 2011
- Immulite/Immulite 1000/IMMULITE 2000/IMMULITE 2500 Psa & 3RD Generation PsaSiemens Healthcare Diagnostics, Inc. · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.